AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial (2022)

First Author: DiNardo C
Attributed to:  University of Oxford – Confidence in Concept 2019 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2152-2650(22)01293-9

Publication URI: https://api.elsevier.com/content/abstract/scopus_id/85138202681

Type: Journal Article/Review

Parent Publication: Clinical Lymphoma Myeloma and Leukemia